Anika Therapeutics (ANIK) Tops Q4 EPS by 28c ; Offers Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- S&P 500, Nasdaq set for higher open as oil prices extend declines, midterm results awaited
- Apple shares slip amid guidance for tightening margins, slowing services growth
- Rising shorts cool U.S. large-cap positioning, cutting liquidation risk: Citi
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
- Goldman data shows hedge funds cut leverage at fastest pace since March
Tweet
Share
E-mailGet Alerts ANIK Hot Sheet
Price: $19.41 --0%
Revenue Growth %: +5.9%
Financial Fact:
Cost of product revenue: 5M
Today's EPS Names:
INM, TRI, CRVL, More
Revenue Growth %: +5.9%
Financial Fact:
Cost of product revenue: 5M
Today's EPS Names:
INM, TRI, CRVL, More
Join SI Premium – FREE
Anika Therapeutics (NASDAQ: ANIK) reported Q4 EPS of $0.05, $0.28 better than the analyst estimate of ($0.23). Revenue for the quarter came in at $43 million versus the consensus estimate of $41.4 million.
GUIDANCE:
Anika Therapeutics sees FY 2024 revenue of $168-173 million, versus the consensus of $179.4 million.
For earnings history and earnings-related data on Anika Therapeutics (ANIK) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Sotera Health Co. (SHC) Tops Q3 EPS by 2c; Offers Guidance
- Shopify (SHOP) Tops Q3 EPS by 2c, Offers Guidance
- IPG Photonics (IPGP) Tops Q3 EPS by 15c ; Offers Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
